Mayo Clinic tie-up aims to speed a one-time type 1 diabetes therapy

AVAI Bio, Vertex, and Sana are developing treatments for Type 1 diabetes by replacing insulin-producing beta cells. Vertex's trial showed 10/12 patients stopped using insulin, but all require immunosuppression. Sana's gene-edited cells evaded immune detection. AVAI Bio's joint venture, Insulinova, is testing encapsulated beta cells with Ospedale San Raffaele. No trials or timelines have been announced.

Sana Biotechnology, Inc. (SANA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continu

AST SpaceMobile (ASTS) and Redwire (RDW) are compared as space infrastructure stocks. ASTS focuses on satellite-based cellular broadband, with revenue growing to $70.9M in FY 2025 but a net loss of $342M. RDW provides space hardware, with $335.4M revenue and a $226.6M net loss. Both face risks and are unprofitable but have growth potential. ASTS trades at $58.77, RDW at $10.75.

Alstom secured 1.2B euro contracts with TransPennine Express for 29 battery-electric trains and maintenance, to be delivered from 2032. Stadler won an order from FS Logistix for eight EUROLIGHT Dual locomotives for Italian rail operations.

Lockheed Martin received a $1.2B contract for the PrSM Increment 2 missile system, according to the Defense Department. The system, designed to hit moving maritime targets, will be developed by 2031. Lockheed's bid was the only one solicited and received. The Army has used PrSM Increment 1 in combat and is planning future increments with enhanced capabilities.

Kraft Heinz launched Philadelphia Mike’s Hot Honey Whipped Cream Cheese, a sweet-and-spicy cream cheese, at Walmart, with a national rollout planned for January 2027. The company is investing $700 million in innovation and marketing to boost sales amid consumer demand pressure. Second-quarter sales were $6.26 billion, down 1.4% year-over-year but beating expectations.